MSAC to review Novartis’ Kymriah
By Megan Brodie 4 years ago | In Cell and gene therapies, Reimbursement- 4 years ago
Deborah Henderson is alive after receiving Kymriah.
24 February 2023 The MSAC will review Novartis’ CAR-T cell therapy KYMRIAH (tisagenlecleucel) when it…
This is subscriber-only content. Please login to continue reading.